Oculis to Showcase Advancements in Ophthalmic Pipeline at Eyecelerator and AAO Annual Meeting

Oculis Holding AG has announced that its late-stage ophthalmic pipeline will be in the spotlight at both Eyecelerator and the American Academy of Ophthalmology (AAO) Annual Meeting, as the company advances several key programs targeting serious eye conditions with limited treatment options.

At Eyecelerator, CEO Dr. Riad Sherif is set to provide a comprehensive update on Oculis’ clinical progress. Among the highlights is the advancement of Privosegtor into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy. This milestone follows a positive meeting with the U.S. Food and Drug Administration, signaling regulatory alignment on the next phase of development for this novel therapy.

Also on the agenda is an update on OCS-01, a topical eye drop formulation currently in Phase 3 development for diabetic macular edema (DME). The DIAMOND program, which evaluates OCS-01 as a non-invasive alternative to injectable therapies, is expected to deliver topline data in the second quarter of 2026. If successful, OCS-01 could reshape the treatment landscape for DME by offering a more patient-friendly route of administration.

In addition, Oculis will share plans for PREDICT-1, an upcoming registrational trial of Licaminlimab in dry eye disease. This trial will take a genotype-driven approach, marking a precision medicine strategy that aims to match patients with treatment based on genetic markers. The study is scheduled to begin in the fourth quarter of 2025.

Beyond the main conference, Oculis will participate in a range of satellite events surrounding the AAO meeting, including Innovate Retina, the inaugural meeting of the Society for Artificial Intelligence in Vision and Ophthalmology (SAIVO), and the COPhy Satellite Symposium. At Innovate Retina, Dr. Arshad Khanani, Chair of Oculis’ Retina Scientific Advisory Board, will join a panel to explore the potential of eye drops like OCS-01 to transform the treatment paradigm for retinal diseases such as DME.

With multiple programs progressing toward pivotal milestones, Oculis is positioning itself at the forefront of innovation in ophthalmology, aiming to deliver impactful, less invasive solutions for patients with high unmet needs.